Last week, readers were most interested in a story about Roche's molecular respiratory panel receiving CE marking.

The FDA clearances address laboratory challenges including staff shortages, limited space, and rising test volumes, the firm said.

The firm also announced its Q4 and full-year 2025 financial results, reporting that revenues for the year doubled compared to 2024.

Clinical labs are exploring new business opportunities as consumers take more control of their healthcare and bypass their ...

The approval marks the eighth FDA-approved CDx indication for the company's PD-L1 IHC 22C3 pharmDx, Code SK006, test for use with Keytruda.

The firm validated its test for one new indication in 64 patients with a variety of solid tumors, including breast, ovarian, melanoma, and head and neck cancers.

Exclusive US distributor Phase Scientific will now roll out the rapid test via an established commercial footprint and other distribution agreements.

An initial $1.35 million has been deployed to the University of California, San Francisco, to initiate the program, with additional funding announcements forthcoming.

With the license, MeMed can offer its BV test, which is intended to distinguish between bacterial and viral infections, in Canada.

NEW YORK – MicrosenseDx, a Cambridge, UK-based diagnostics developer, has inked a strategic partnership with France's ProteoGenix to speed up development of a rapid diagnostic test for sepsis.

NEW YORK – Laboratory Corporation of America said in a filing with the US Securities and Exchange Commission on Friday that it has entered into an agreement for a term loan of $750 million. The ...

The test detects up to 25 viral and bacterial targets, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in one patient sample.